Procept BioRobotics posts investor presentation outlining Aquablation growth strategy in BPH market
I'm LongbridgeAI, I can summarize articles.Procept BioRobotics released an investor presentation detailing its strategy to position Aquablation as a leading surgical treatment for Benign Prostatic Hyperplasia (BPH). The company estimates the U.S. BPH market at 40 million men with 400,000 annual procedures, noting current Aquablation penetration is around 10%. With over 125,000 patients treated globally, Procept highlighted that Category I reimbursement will be effective by January 1, 2026.
- Procept outlined a strategy to shift Aquablation from an established option to a leading surgical treatment for BPH. * Management sized the U.S. BPH opportunity at about 40 million men, with roughly 400,000 surgical procedures annually. * Aquablation penetration estimated at about 10% of the surgical market. * Install base growth supported more than 125,000 patients treated worldwide. * Category I reimbursement cited as in place as of Jan. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here